2017
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Namioka T, Namioka A, Onodera R, Suzuki J, Sasaki Y, Nagahama H, Mikami T, Wanibuchi M, Kocsis JD, Honmou O. Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats. Journal Of Neurosurgery 2017, 127: 917-926. PMID: 28059661, DOI: 10.3171/2016.8.jns16240.Peer-Reviewed Original ResearchConceptsTransient middle cerebral artery occlusionRecombinant tissue plasminogen activatorMiddle cerebral artery occlusionRegional cerebral blood flowCerebral artery occlusionMesenchymal stem cellsHemorrhagic eventsArtery occlusionEndothelial dysfunctionRtPA therapyIntracerebral hemorrhageIntravenous infusionIncidence rateNormal salineIntravenous recombinant tissue plasminogen activatorRecombinant tissue plasminogen activator therapyTissue plasminogen activator therapyInfused mesenchymal stem cellsMatrix metalloproteinase-9 levelsEarly behavioral recoveryNon-rtPA groupAcute ischemic strokeVascular endothelial dysfunctionExperimental stroke modelsMetalloproteinase-9 levels
2015
On- versus Off-Hour Patient Cohorts at a Primary Stroke Center: Onset-to-Treatment Duration and Clinical Outcomes after IV Thrombolysis
Asuzu D, Nystrӧm K, Amin H, Schindler J, Wira C, Greer D, Fang NF, Halliday J, Sheth KN. On- versus Off-Hour Patient Cohorts at a Primary Stroke Center: Onset-to-Treatment Duration and Clinical Outcomes after IV Thrombolysis. Journal Of Stroke And Cerebrovascular Diseases 2015, 25: 447-451. PMID: 26654664, DOI: 10.1016/j.jstrokecerebrovasdis.2015.10.017.Peer-Reviewed Original ResearchConceptsSymptomatic intracerebral hemorrhagePrimary stroke centerClinical outcomesStroke centersStroke severitySymptom onsetStroke careStroke patientsPatient cohortIntravenous recombinant tissue plasminogen activator (rt-PA) therapyTreatment durationRecombinant tissue plasminogen activator therapyHealth Stroke Scale scoreTissue plasminogen activator therapyConsistent quality careBaseline National InstitutesStroke Scale scoreAcute stroke careIschemic stroke patientsPlasminogen activator therapyMann-Whitney testSICH rateAcute strokeIschemic strokeConsecutive patients
2013
Postthrombolysis Outcomes in Acute Ischemic Stroke Patients of Asian Race-Ethnicity
Mishra NK, Chan BP, Teoh H, Meng C, Lees KR, Chen C, Sharma VK. Postthrombolysis Outcomes in Acute Ischemic Stroke Patients of Asian Race-Ethnicity. International Journal Of Stroke 2013, 8: 95-99. PMID: 23490069, DOI: 10.1111/ijs.12012.Peer-Reviewed Original ResearchConceptsVirtual International Stroke Trials ArchiveThrombolytic therapyStroke patientsAsian patientsHealth Stroke Scale scorePropensity score-matched patientsAcute ischemic stroke patientsTissue plasminogen activator therapyAsian stroke patientsBaseline National InstitutesPropensity-matched cohortStroke Scale scoreIschemic stroke patientsProportional odds logistic regression analysisPlasminogen activator therapyNational University HospitalLogistic regression analysisNational InstituteRace-ethnic differencesNeurological outcomeRankin scoreThrombolyzed patientsPropensity matchingTertiary centerActivator therapy
2011
Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?
Reeves M, Grau-Sepulveda M, Fonarow G, Olson D, Smith E, Schwamm L. Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation? Circulation Cardiovascular Quality And Outcomes 2011, 4: 503-511. PMID: 21828344, DOI: 10.1161/circoutcomes.111.961755.Peer-Reviewed Original ResearchConceptsGuidelines-Stroke programAtrial fibrillation/flutterIntravenous recombinant tissue plasminogen activator (rt-PA) therapyRecombinant tissue plasminogen activator therapyDeep vein thrombosis prophylaxisTissue plasminogen activator therapyBetter careTarget populationGWTG-Stroke hospitalsIschemic stroke admissionsPlasminogen activator therapyNumber of patientsProportion of subjectsData collection formDischarge antithromboticsEarly antithromboticsThrombosis prophylaxisTreatment contraindicationsEligible subjectsStroke admissionsActivator therapySmoking cessationLipid therapyMeasure complianceContraindications
2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window
Saver J, Gornbein J, Grotta J, Liebeskind D, Lutsep H, Schwamm L, Scott P, Starkman S. Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window. Stroke 2009, 40: 2433-2437. PMID: 19498197, PMCID: PMC2724988, DOI: 10.1161/strokeaha.108.543561.Peer-Reviewed Original ResearchConceptsTissue plasminogen activatorRankin ScaleIntravenous tissue plasminogen activator therapyIntravenous tissue plasminogen activatorTissue plasminogen activator therapyPlasminogen activatorAcute cerebral ischemiaModified Rankin ScalePlasminogen activator therapyResults of therapyEffect sizeCerebral ischemiaPoststroke disabilityAdditional patientsActivator therapyWorse outcomesGlobal disabilityTreatment decisionsBetter outcomesClinical practicePatientsNNTBLikelihood of helpEffect size estimatesTable analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply